PCSK9-BIRC2 in vitro Binding Assay Kit

• Cat.No.: Kit-0665
• Product Overview: PCSK9-BIRC2 in vitro Binding Assay Kit is used for characterizing and inhibitor screening of PCSK9-BIRC2 interaction in vitro.

Specification

• Applications: 1. Screening inhibitors of PCSK9-eIAP1 interaction in vitro.2. Characterization of inhibitor candidates of PCSK9-cIAP1 interaction in vitro.3. Screening monoclonal antibody that inhibits PCSK9-cIAP1 interaction in vitro.4. Characterization of PCSK9-cIAP1 interaction in vitro
• Storage: Upon receipt store all components at 4°C.Do not expose reagents to excessive light.

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.